“The third quarter of 2023 was momentous for Neumora with the achievement of several important clinical and corporate milestones, including our successful initial public offering and the initiation of our Phase 3 KOASTAL program for navacaprant. Additionally, we are on track to achieve the anticipated milestones for NMRA-511 and NMRA-266,” said Henry Gosebruch, chief executive officer, Neumora. “Looking forward, we have a strong balance sheet to support our continued focus on execution across our programs as we seek to pioneer a new era in brain diseases, which collectively represent one of the largest areas of unmet medical need, affecting upwards of 1.5 billion patients globally. I believe that we have the right combination of novel programs and capabilities to make a real difference for patients living with brain diseases and create significant value.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NMRA:
- Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Neumora Therapeutics to Participate in Upcoming Conferences in November
- Neumora initiated with Outperform, $26 fair value at William Blair
- Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
- Neumora Therapeutics appoints Lenz as EVP, Head of Research, Development